Antimicrobial Susceptibility Trends Among Staphylococcus aureus from United States Hospitals:
|
|
- Lindsay Riley
- 5 years ago
- Views:
Transcription
1 AAC Accepted Manuscript Posted Online 19 June 2017 Antimicrob. Agents Chemother. doi: /aac Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 Antimicrobial Susceptibility Trends Among Staphylococcus aureus from United States Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program ( ) Running title: Antimicrobial susceptibility of S. aureus in the U.S. Helio S. Sader, Rodrigo E. Mendes, Jennifer M. Streit, Robert K. Flamm JMI Laboratories, North Liberty, Iowa, USA Key words: Methicillin-resistant Staphylococcus aureus, MRSA, skin and skin structure infection, ceftaroline, cephalosporin Contact Information: Helio S. Sader, M.D., Ph.D. JMI Laboratories 345 Beaver Kreek Centre, Suite A North Liberty, IA Phone: (319) Fax: (319) helio-sader@jmilabs.com 1
2 Abstract We evaluated trends in Staphylococcus aureus antimicrobial susceptibility in United States hospitals in the period. A total of 21,056 clinical isolates from 42 medical centers were tested for susceptibility by broth microdilution methods. MRSA rates decreased from 50.0% (2010) to 42.2% (2016). Susceptibility to erythromycin, levofloxacin, and clindamycin increased slightly, whereas susceptibility to ceftaroline, trimethoprim-sulfamethoxazole, and tetracycline remained stable. Ceftaroline retained potent activity against MSSA and MRSA (97.2% susceptible) with no marked variations. Count: 74 words. Downloaded from on September 2, 2018 by guest 2
3 Staphylococcus aureus and Escherichia coli represent the most common pathogens causing infection in hospitalized patients in the United States (U.S.) (1), and infections caused by antimicrobial-resistant S. aureus, especially methicillin-resistant (MRSA) strains, often occur in epidemic waves initiated by 1 or a few successful clones. These "epidemic waves" are not uniformly spread around the globe, but tend to be delimited somewhat by continent or smaller world regions (2, 3). Thus, the epidemiology of MRSA in U.S. hospitals is constantly changing, requiring continuous monitoring of its antimicrobial resistance profile (4). Ceftaroline fosamil (Teflaro ), prodrug of ceftaroline, was approved in 2010 by the U.S. Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) due to susceptible isolates of S. aureus (including methicillin-susceptible [MSSA] and MRSA isolates), Streptococcus pyogenes, Streptococcus agalactiae, E. coli, Klebsiella pneumoniae, and Klebsiella oxytoca. Ceftaroline fosamil was also approved for community-acquired bacterial pneumonia (CABP) due to Streptococcus pneumoniae (including cases with concurrent bacteremia), S. aureus (MSSA only), Haemophilus influenzae, K. pneumoniae, K. oxytoca, and E. coli (5, 6). The antimicrobial resistance surveillance program Assessing Worldwide Antimicrobial Resistance and Evaluation (AWARE) was designed to monitor the activity of ceftaroline and comparator agents and provides contemporary and longitudinal information on the activity of this agent against relevant pathogens. Previous reports from the AWARE program have provided analyses of ceftaroline activity against bacterial isolates recovered from indicated sites of infections, specific patient populations, and selected organism groups and resistant subsets, as well as yearly variation on its in vitro activity and potency (7-10). In this investigation we evaluated trends in S. aureus susceptibility rates to ceftaroline and comparators in the period. Clinically significant bacterial isolates were consecutively collected (1/patient) from various infection types and all S. aureus isolates (n=21,056) were from patients hospitalized in medical centers that participated in the AWARE Program. Isolates were from 42 medical centers located in 30 states (from all 9 census divisions), including (number of medical centers): Alaska (1), Alabama (1), Arkansas (1), Colorado (1), Illinois (1), Indiana (1), Iowa (1), Kentucky (2), Louisiana (1), Maine (1), Massachusetts (1), Michigan (2), Minnesota (2), Missouri (1), Nebraska (1), New Jersey (2), New Mexico (1), New York (3), North Carolina (1), North Dakota (1), Ohio (3), Oregon (1), Pennsylvania (1), Tennessee (1), Texas (3), Utah (1), Vermont (1), Virginia (1), Washington (2), and Wisconsin (2). Forty of these 42 medical centers participated in the AWARE Program 3
4 during the entire period of this investigation ( ), and the remaining 2 centers contributed isolates from Isolates were tested for susceptibility to ceftaroline and multiple comparator agents by reference broth microdilution methods as described by Clinical and Laboratory Standard Institute (CLSI) M07-A10, and susceptibility interpretations were based on CLSI (M100-S27) and/or U.S. FDA, as well as EUCAST breakpoint criteria (6, 11-14). A susceptible breakpoint of 1 μg/ml was applied for ceftaroline as indicated by CLSI and EUCAST and based on ceftaroline fosamil 600 mg q12h dosage (6). MIC panels were manufactured at JMI Laboratories ( ) (North Liberty, Iowa, USA) or purchased from Thermo Fisher Scientific ( ) (Cleveland, Ohio, USA). Organisms were tested in cationadjusted Mueller-Hinton broth (Thermo Fisher Scientific). Ceftaroline and comparator agents were tested simultaneously using the same bacterial inoculum and testing reagents. Concurrent testing of quality control (QC) strains assured proper test conditions. All QC results were within CLSI published ranges (12). Yearly variation of susceptibility rates was evaluated by using CLSI susceptible breakpoints (M100-S27) (12) and applying Chi-square test for trend with the EpiInfo TM 7 software. S. aureus isolates evaluated in this investigation were collected from patients with skin and skin structure infections (52.0%), pneumonia (23.9%), bloodstream infections (16.8%), and other infection types (7.3%). Ceftaroline inhibited all S. aureus strains at 2 µg/ml, except for 1 isolate collected in 2016 from a patient with complicated urinary tract infection with a ceftaroline MIC of 4 μg/ml. Furthermore, ceftaroline susceptibility rates remained stable during the study period, with a high of 99.4% in 2010 and a low of 98.1% in 2014; 98.7% overall (Tables 1 and 2). MRSA rates showed a clear decrease during the investigation, varying from 50.0% in 2010 to a low of 42.2% in 2016 (p<0.01; 46.0% overall; Tables 1 and 2). Susceptibility (per CLSI) to levofloxacin oscillated from a low of 61.5% in 2011 and 2013 to a high of 64.0% in 2012 and Susceptibility (per CLSI) to erythromycin varied from a low of 38.5% in 2013 to a high of 44.1% in 2016, with a strong trend toward higher susceptibility rates during the last 4 years of the investigation ( ; p<0.01); whereas susceptibility (per CLSI) to clindamycin remained practically stable during the period of the investigation, varying from 83.7% in 2010 to 85.0% in 2016 (Table 2). Susceptibility (per CLSI) to tetracycline and trimethoprim-sulfamethoxazole (TMP- SMX) also remained stable during the period of the study (Table 2). 4
5 When tested against MSSA, ceftaroline (MIC 50/90, 0.25/0.25 μg/ml; 100.0% susceptible) was 16-fold more active than ceftriaxone (MIC 50/90, 4/4 μg/ml; 100.0% susceptible; Table 1). MSSA susceptibility rates (per CLSI) remained stable for clindamycin (94.1/95.8% in 2010/2016), levofloxacin (88.6/89.3% in 2010/2016), and tetracycline (95.3/96.9% in 2010/2016), and oscillated from a low of 63.2% in 2012 to a high of 68.3% in 2010 for erythromycin (68.3/67.7% in 2010/2016), with no clear trend in any direction during the investigation (Table 2). Ceftaroline was very active against MRSA (MIC 50/90, 0.5/1 µg/ml; 97.2% susceptible overall; Table 1) with susceptibility rates varying from 98.8% in 2010 to 96.7% in The highest susceptibility rate (98.8%) was observed in 2010 and the lowest (95.6%) in 2014 (Table 2). MRSA susceptibility rates (per CLSI) for clindamycin and levofloxacin showed a decreasing trend from 2010 to 2016 to a low of 70.3% for clindamycin (p=0.01) and 28.6% for levofloxacin (p<0.01; Table 2). Daptomycin (MIC 50/90, 0.25/0.5 μg/ml; 99.9% susceptible), linezolid (MIC 50/90, 1/1 μg/ml; >99.9% susceptible), tigecycline (MIC 50/90, 0.06/0.12 μg/ml; >99.9% susceptible), vancomycin (MIC 50/90, 1/1 μg/ml; >99.9% susceptible), and TMP-SMX (MIC 50/90, 0.5/ 0.5 μg/ml; 97.7% susceptible) were also very active against MRSA overall (Table 1) with no marked variation during the study period (yearly data for TMP-SMX are presented in Table 2). Tetracycline also showed good and stable in vitro activity against MRSA over the years with susceptibility rates (per CLSI) varying from a low of 92.8% in 2015 to a high of 95.7% in 2016 (Table 2). MRSA epidemiology in the U.S. changed considerably as community-acquired MRSA (CA-MRSA) emerged and rapidly disseminated in the late 1990s (15). CA-MRSA was first noted as a genotypically distinct clone of MRSA (identified as USA300 by pulsed-field gel electrophoresis) that emerged as an important cause of SSSI as well as severe invasive syndromes in patients with no known exposure to a health care environment (3). The susceptibility pattern of USA300 was initially described as being susceptible to TMP-SMX, clindamycin, and tetracycline, but resistant to erythromycin and variably susceptible to the fluoroquinolones (16, 17); however, local spread of multidrug-resistant USA300 clones has been reported (18-20). Although USA300 is still the main S. aureus clone causing community-acquired and health careassociated infections in many parts of the U.S., its prevalence seems to be decreasing in some areas (4, 21). Chambers and DeLeo (2) have shown that the epidemiology of S. aureus is continually changing, with strains containing different antimicrobial susceptibility patterns replacing each other as the dominant clone. Thus, a 5
6 decrease in the USA300 prevalence may result in changes in the antimicrobial resistance profiles of S. aureus, emphasizing the importance of monitoring this organism through large resistance surveillance programs. These investigation results clearly showed a continued decrease in MRSA rates between 2010 and 2016 in the hospitals participating in the AWARE program. Susceptibility to other agents, such as levofloxacin, clindamycin, and erythromycin, also showed some increase during the same period, whereas susceptibility to ceftaroline, TMP-SMX, and tetracycline remained stable. Furthermore, ceftaroline retained potent in vitro activity against MRSA (97.2% susceptible) and MSSA (100.0% susceptible) with no marked variations or trends (MIC creep) during the study period. It is also important to note that during this investigation, resistance to daptomycin, linezolid, vancomycin, or tigecycline remained extremely rare among S. aureus with no sign of increasing (data not shown). The absence of data on the incidence of S. aureus and MRSA infections in the medical centers that provided bacterial isolates represents a limitation of the study. Without incidence data it is not possible to evaluate if the decreased MRSA rates observed in this investigation were caused by a real decrease in the incidence of MRSA infections or by a proportional increase in the occurrence of MSSA infections. Another limitation of the study is the restricted number of medical centers included in the investigation. Despite these limitations, the results presented provide valuable information on the evolving S. aureus antimicrobial susceptibility patterns in the U.S. medical centers that participate in the AWARE program. 6
7 145 Acknowledgements The authors would like to thank all participants of the Assessing Worldwide Antimicrobial Resistance and Evaluation (AWARE) Program for providing bacterial isolates. This study was supported by Allergan. Allergan was involved in the design and decision to present these results, and JMI Laboratories received compensation fees for services in relation to preparing this manuscript. Allergan was not involved in the collection, analysis, or interpretation of data. JMI Laboratories contracted to perform services in 2016 for Achaogen, Actelion, Allecra Therapeutics, Allergan, AmpliPhi Biosciences, API, Astellas Pharma, AstraZeneca, Basilea Pharmaceutica, Bayer AG, BD, Biomodels, Cardeas Pharma Corp., CEM-102 Pharma, Cempra, Cidara Therapeutics, Inc., CorMedix, CSA Biotech, Cutanea Life Sciences, Inc., Debiopharm Group, Dipexium Pharmaceuticals, Inc., Duke, Entasis Therapeutics, Inc., Fortress Biotech, Fox Chase Chemical Diversity Center, Inc., Geom Therapeutics, Inc., GSK, Laboratory Specialists, Inc., Medpace, Melinta Therapeutics, Inc., Merck & Co., Inc., Micromyx, MicuRx Pharmaceuticals, Inc., Motif Bio, N8 Medical, Inc., Nabriva Therapeutics, Inc., Nexcida Therapeutics, Inc., Novartis, Paratek Pharmaceuticals, Inc., Pfizer, Polyphor, Rempex, Scynexis, Shionogi, Spero Therapeutics, Symbal Therapeutics, Synlogic, TenNor Therapeutics, TGV Therapeutics, The Medicines Company, Theravance Biopharma, ThermoFisher Scientific, VenatoRx Pharmaceuticals, Inc., Wockhardt, Zavante Therapeutics, Inc. There are no speakers bureaus or stock options to declare. 7
8 166 References Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, Infect Control Hosp Epidemiol 37: Chambers HF, Deleo FR Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7: David MZ, Daum RS Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 23: Planet PJ Life After USA300: The rise and fall of a superbug. J Infect Dis 215:S71-S Frampton JE Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs 73: Teflaro Package Insert. Allergan, Available at Accessed August Sader HS, Flamm RK, Jones RN Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin or vancomycin from USA hospitals ( ). Antimicrob Agents Chemother 57: Sader HS, Mendes RE, Farrell DJ, Flamm RK, Jones RN Ceftaroline activity tested against bacterial isolates from pediatric patients: Results from the assessing worldwide antimicrobial resistance and evaluation program for the United States ( ). Pediatr Infect Dis J 33: Sader HS, Farrell DJ, Mendes RE, Flamm RK, Castanheira M, Jones RN Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in Diagn Microbiol Infect Dis 82: Sader HS, Farrell DJ, Flamm RK, Jones RN Antimicrobial activity of ceftaroline tested against Staphylococcus aureus from surgical skin and skin structure infections in US Medical Centers. Surg Infect (Larchmt) 17: CLSI M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition. Clinical and Laboratory Standards Institute, Wayne, PA. 8
9 CLSI M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA. 13. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 7.0, January European Committee on Antimicrobial Susceptibility Testing. 14. Tygacil Package Insert. Wyeth Pharmaceuticals, Available at Accessed February 23, Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279: Chua K, Laurent F, Coombs G, Grayson ML, Howden BP Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 52: Mendes RE, Sader HS, Deshpande LM, Diep BA, Chambers HF, Jones RN Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from Phase IV clinical trial for linezolid. J Clin Microbiol 48: Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F Emergence of multidrug-resistant, community-associated, methicillinresistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 148: Popovich KJ, Weinstein RA, Hota B Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis 46: Otto M Community-associated MRSA: what makes them special? Int J Med Microbiol 303: David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG, Jr., Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ, Garcia-Houchins S, Gialanella P, Macias-Gil R, Rude TH, Ruffin F, Sieth 9
10 JJ, Volinski J, Spellberg B Staphylococcus aureus bacteremia at 5 US academic medical centers, : Significant geographic variation in community-onset infections. Clin Infect Dis 59:
11 Table 1 Activity of ceftaroline and comparator antimicrobial agents when tested against 21,056 Staphylococcus aureus isolates ( ) Organism / antimicrobial a CLSI agent (no. tested) MIC 50 MIC 90 S. aureus (21,056) EUCAST a %S %R %S %R Ceftaroline < Ceftriaxone 4 > Oxacillin 1 > Erythromycin >4 > Clindamycin 0.25 > Levofloxacin 0.5 > TMP-SMX b Tetracycline Tigecycline >99.9 c >99.9 <0.1 Linezolid 1 1 >99.9 <0.1 >99.9 <0.1 Vancomycin 1 1 > >99.9 <0.1 Daptomycin MSSA (11,377) Ceftaroline Ceftriaxone 4 4 Erythromycin 0.25 > Clindamycin Levofloxacin TMP-SMX b Tetracycline Tigecycline c Linezolid 1 1 >99.9 <0.1 >99.9 <0.1 Vancomycin Daptomycin >99.9 >99.9 <0.1 MRSA (9,679) Ceftaroline < Erythromycin >4 > Clindamycin 0.25 > Levofloxacin 4 > TMP-SMX b Tetracycline
12 Organism / antimicrobial a CLSI agent (no. tested) MIC 50 MIC 90 EUCAST a %S %R %S %R Tigecycline >99.9 c >99.9 <0.1 Linezolid 1 1 >99.9 <0.1 >99.9 <0.1 Vancomycin 1 1 > >99.9 <0.1 Daptomycin a Criteria as published by CLSI (12) and EUCAST (13) b TMP-SMX, trimethoprim-sulfamethoxazole c Breakpoints from US FDA Package Insert (14) Downloaded from on September 2, 2018 by guest 12
13 233 Table 2. Staphylococcus aureus antimicrobial susceptibility stratified by year ( ) Organism/ % susceptible (CLSI) a year (no.) Ceftaroline Oxacillin Erythromycin Clindamycin Levofloxacin Tetracycline TMP-SMX b S. aureus 2010 (1,364) (1,370) (4,131) (4,123) (3,026) (3,506) (3,536) MSSA 2010 (682) (695) (2,214) (2,092) (1,673) (1,978) (2,043) MRSA 2010 (682) (675) (1,917) (2,031) (1,353) (1,528) (1,493) a Criteria as published by CLSI (12) b TMP-SMX, trimethoprim-sulfamethoxazole 13
In Vitro Activity of Tedizolid against Gram-Positive Cocci Isolates from Patients
Research Article imedpub Journals www.imedpub.com Journal of Infectious Diseases and Treatment DOI: 10.21767/2472-1093.100040 In Vitro Activity of Tedizolid against Gram-Positive Cocci Isolates from Patients
More informationon April 8, 2018 by guest
AAC Accepted Manuscript Posted Online 9 January 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.02252-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 4 Antimicrobial
More informationIn vitro Activity Evaluation of Telavancin against a Contemporary Worldwide Collection of Staphylococcus. aureus. Rodrigo E. Mendes, Ph.D.
AAC Accepts, published online ahead of print on 12 April 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00301-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationSUPPLEMENT ARTICLE. Michael A. Pfaller, David J. Farrell, Helio S. Sader, and Ronald N. Jones. JMI Laboratories, North Liberty, Iowa
SUPPLEMENT ARTICLE AWARE Ceftaroline Surveillance Program (2008 2010): Trends in Resistance Patterns Among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationZyvox w Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years ( )
J Antimicrob Chemother 2014; 69: 1582 1588 doi:10.1093/jac/dkt541 Advance Access publication 26 January 2014 Zyvox w Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationStates with Authority to Require Veterinarians to Report to PMP
States with Authority to Require Veterinarians to Report to PMP Research current through December 2014. This project was supported by Grant No. G1399ONDCP03A, awarded by the Office of National Drug Control
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationNew Antibiotics for MRSA
New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker
More informationSUPPLEMENT ARTICLE. among clinical isolates of S. pneumoniae in the United
SUPPLEMENT ARTICLE Regional Trends in Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: Results from
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationANTIMICROBIAL SUSCEPTIBILITY DETECTION OF ELEVATED MICs TO PENICILLINS IN β- HAEMOLYTIC STREPTOCOCCI
HAEMOLYTIC STREPTOCOCCI This specimen was designated as a sample from a skin wound that was to be cultured, identified to species level and susceptibility tested [1-3]. The culture contained a Streptococcus
More informationActivity of Linezolid Tested Against Uncommonly Isolated Gram-positive ACCEPTED
AAC Accepts, published online ahead of print on 8 January 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01496-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationSUPPLEMENT ARTICLE. S114 CID 2001:32 (Suppl 2) Diekema et al.
SUPPLEMENT ARTICLE Survey of Infections Due to Staphylococcus Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe,
More informationANTIMICROBIAL SUSCEPTIBILITY CONTEMPORARY SUSCEPTIBILITY TESTS AND TREATMENTS FOR VRE INFECTIONS
TREATMENTS FOR VRE INFECTIONS Sample ES-01 (2015) was a simulated blood culture isolate from a patient with associated clinical symptoms (pure culture). Participants were requested to identify any potential
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationHong-Kai Wang 1, Chun-Yen Huang 1 and Yhu-Chering Huang 1,2*
Wang et al. BMC Infectious Diseases (2017) 17:470 DOI 10.1186/s12879-017-2560-0 RESEARCH ARTICLE Open Access Clinical features and molecular characteristics of childhood communityassociated methicillin-resistant
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA
ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationSTAPHYLOCOCCI: KEY AST CHALLENGES
Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection
More informationMethicillin Resistant Staphylococcus Aureus (MRSA) The drug resistant `Superbug that won t die
Methicillin Resistant Staphylococcus Aureus (MRSA) The drug resistant `Superbug that won t die Michael A. Miller, MD Assistant Professor of Pediatrics -Jacksonville OBJECTIVES 1. Understand the basic microbiology
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01550.x Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002 2004)
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationIn vitro activity of telavancin against recent Gram-positive clinical isolates: results of the Prospective European Surveillance Initiative
Journal of Antimicrobial Chemotherapy (2008) 62, 116 121 doi:10.1093/jac/dkn124 Advance Access publication 19 April 2008 In vitro activity of telavancin against recent Gram-positive clinical isolates:
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationMRSA. ( Staphylococcus aureus; S. aureus ) ( community-associated )
005 16 190-194 ( Staphylococcus aureus; S. aureus ) ( community-associated ) ( -susceptible Staphylococcus auerus; MSSA ) ( -resistant Staphylococcus auerus; ) ( ) ( -lactam ) ( glycopeptide ) ( Staphylococcus
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationTACKLING THE MRSA EPIDEMIC
TACKLING THE MRSA EPIDEMIC Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine MRSA Trend (HA + CA) in US TSN Database USA (1993-2003) % of MRSA among S. aureus
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationMicrobiological and Genotypic Analysis of Methicillin-Resistant ACCEPTED. 1. Department of Medicine, New York Medical College, Valhalla, NY
AAC Accepts, published online ahead of print on 7 July 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00357-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationLack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
Infect Dis Ther (2014) 3:55 59 DOI 10.1007/s40121-014-0028-8 BRIEF REPORT Lack of Change in Susceptibility of Pseudomonas aeruginosa in a Pediatric Hospital Despite Marked Changes in Antibiotic Utilization
More informationMRSA surveillance 2014: Poultry
Vicky Jasson MRSA surveillance 2014: Poultry 1. Introduction In the framework of the FASFC surveillance, a surveillance of MRSA in poultry has been executed in order to determine the prevalence and diversity
More informationANTIMICROBIAL SUSCEPTIBILITY CHARACTERIZING SUSCEPTIBILITY PATTERNS OF MSSA ASSOCIATED WITH SURGICAL WOUND INFECTIONS
ASSOCIATED WITH SURGICAL WOUND INFECTIONS Specimen ES-02 was designated as a "surgical wound culture" to be identified to the species level and tested for antimicrobial susceptibility. 1-4 The culture
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationSTATISTICAL BRIEF #35
HEALTHCARE COST AND UTILIZATION PROJECT STATISTICAL BRIEF #35 Agency for Healthcare Research and Quality July 2007 Infections with Methicillin-Resistant Staphylococcus Aureus (MRSA) in U.S. Hospitals,
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationMolecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus bacteremia in a teaching hospital
Epidemiology J Microbiol Immunol of MRSA Infect. bacteremia 2007;40:310-316 Molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus bacteremia in a teaching hospital Chih-Yu
More informationIn vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains
Eur J Clin Microbiol Infect Dis (2010) 29:503 507 DOI 10.1007/s10096-010-0886-2 ARTICLE In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated
More informationThe Economic Impacts of the U.S. Pet Industry (2015)
The Economic s of the U.S. Pet Industry (2015) Prepared for: The Pet Industry Joint Advisory Council Prepared by: Center for Regional Analysis George Mason University February 2017 1 Center for Regional
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationSURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS
SURVIVABILITY OF HIGH RISK, MULTIRESISTANT BACTERIA ON COTTON TREATED WITH COMMERCIALLY AVAILABLE ANTIMICROBIAL AGENTS Adrienn Hanczvikkel 1, András Vígh 2, Ákos Tóth 3,4 1 Óbuda University, Budapest,
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationFM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...
Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationContinued in vitro cefazolin susceptibility in methicillin susceptible Staphylococcus aureus
https://doi.org/10.1186/s12941-018-0257-x Annals of Clinical Microbiology and Antimicrobials SHORT REPORT Open Access Continued in vitro cefazolin susceptibility in methicillin susceptible Staphylococcus
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationSurveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler
Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations
More informationAntimicrobial Activity of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired ACCEPTED. Helio S Sader 1,2 *,
AAC Accepts, published online ahead of print on 7 January 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.01351-07 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationAn Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus
Article ID: WMC00590 ISSN 2046-1690 An Approach to Linezolid and Vancomycin against Methicillin Resistant Staphylococcus Aureus Author(s):Dr. K P Ranjan, Dr. D R Arora, Dr. Neelima Ranjan Corresponding
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationRESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN
RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VANCOMYCIN IN ZARQA, JORDAN Hussein Azzam Bataineh 1 ABSTRACT Background: Vancomycin has been widely used in the treatment of infections caused by Methicillin-Resistant
More informationAntibiotic Resistances Profile in Iran, Clinical Implication and Prospect for Antibiotic Stewardship Jafar Soltani
Antibiotic Resistances Profile in Iran, Clinical Implication and Prospect for Antibiotic Stewardship Jafar Soltani Pediatrics Department, Faculty of Medicine, Kurdistan University of Medical Sciences,
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationProceedings of the 19th American Academy of Veterinary Pharmacology and Therapeutics Biennial Symposium
www.ivis.org Proceedings of the 19th American Academy of Veterinary Pharmacology and Therapeutics Biennial Symposium May 17-20, 2015 Fort Collins, CO, USA Reprinted in the IVIS website with the permission
More informationPoultry - Production and Value 2017 Summary
United States Department of Agriculture National Agricultural Statistics Service Poultry - Production and Value 207 Summary ISSN: 949-573 April 208 Contents Summary... 5 Broiler Production and Value States
More informationReceived 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 3112 3118 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.3112 3118.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationSIVEXTRO (tedizolid phosphate) oral tablet ZYVOX (linezolid) oral suspension and tablet
ZYVOX (linezolid) oral suspension and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationAnnual Surveillance Summary: Methicillinresistant Staphylococcus aureus (MRSA) Infections in the Military Health System (MHS), 2017
Annual Surveillance Summary: Methicillinresistant Staphylococcus aureus (MRSA) Infections in the Military Health System (MHS), 2017 Jessica R. Spencer and Uzo Chukwuma Approved for public release. Distribution
More informationDynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
2011 International Conference on Biomedical Engineering and Technology IPCBEE vol.11 (2011) (2011) IACSIT Press, Singapore Dynamic Drug Combination Response on Pathogenic Mutations of Staphylococcus aureus
More informationSURVEILLANCE REPORT #92. August 2011
National Institute on Alcohol Abuse and Alcoholism Division of Epidemiology and Prevention Research Alcohol Epidemiologic Data System SURVEILLANCE REPORT #92 APPARENT PER CAPITA ALCOHOL CONSUMPTION: NATIONAL,
More information